Incidence of sudden cardiac death associated with hypertension and left ventricular hypertrophy is reduced by chronic β-adrenergic blockade

Kevin C Dellsperger, J. B. Martins, J. L. Clothier, M. L. Marcus

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Because β-adrenergic blockade has as one of its many effects altered electrophysiological abnormalities after dogs with left ventricular hypertrophy have been subjected to coronary occlusion, we tested the hypothesis that metoprolol (200-400 mg/day) would reduce mortality rates in dogs with one-kidney, one clip left ventricular hypertrophy while a similar reduction in arterial pressure with enalapril (20-40 mg/day) would not. Dogs with left ventricular hypertrophy were given metoprolol or enalapril for 5-7 days before a 3-hour coronary occlusion. Infarct size and risk area were measured with triphenyltetrazolium chloride stain and barium angiography, respectively. For control (n = 15), left ventricular hypertrophy (n =17), left ventricular hypertrophy plus metoprolol (n = 12), and left ventricular hypertrophy plus enalapril (n = 15) groups, mean arterial pressure, ratio of infarct size to risk area, and dogs experiencing sudden death were 110 ± 4, 142 ± 4, 121 ± 7, and 120 ± 3 mm Hg; 44 ± 5%, 65 ± 5%, 44% ± 7%, and 30 ± 4%; and 27%, 65%, 17%, and 53%, respectively. Thus, the excessive increase in early mortality occurring when dogs with hypertension and left ventricular hypertrophy undergo coronary occlusion is interrupted with β-blockade, possibly via electrophysiological effects rather than by changes in arterial pressure or infarct size.

Original languageEnglish (US)
Pages (from-to)941-950
Number of pages10
JournalCirculation
Volume82
Issue number3
DOIs
StatePublished - Jan 1 1990

Fingerprint

Sudden Cardiac Death
Left Ventricular Hypertrophy
Adrenergic Agents
Hypertension
Incidence
Enalapril
Metoprolol
Dogs
Coronary Occlusion
Arterial Pressure
Mortality
Barium
Sudden Death
Surgical Instruments
Angiography
Coloring Agents
Kidney

Keywords

  • Enalapril
  • Hypertension
  • Left ventricular hypertrophy
  • Metroprolol
  • Occlusions
  • β-adrenergic blockers

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Incidence of sudden cardiac death associated with hypertension and left ventricular hypertrophy is reduced by chronic β-adrenergic blockade. / Dellsperger, Kevin C; Martins, J. B.; Clothier, J. L.; Marcus, M. L.

In: Circulation, Vol. 82, No. 3, 01.01.1990, p. 941-950.

Research output: Contribution to journalArticle

Dellsperger, Kevin C ; Martins, J. B. ; Clothier, J. L. ; Marcus, M. L. / Incidence of sudden cardiac death associated with hypertension and left ventricular hypertrophy is reduced by chronic β-adrenergic blockade. In: Circulation. 1990 ; Vol. 82, No. 3. pp. 941-950.
@article{e97eccfc51c6451a97a1cf654ab092e1,
title = "Incidence of sudden cardiac death associated with hypertension and left ventricular hypertrophy is reduced by chronic β-adrenergic blockade",
abstract = "Because β-adrenergic blockade has as one of its many effects altered electrophysiological abnormalities after dogs with left ventricular hypertrophy have been subjected to coronary occlusion, we tested the hypothesis that metoprolol (200-400 mg/day) would reduce mortality rates in dogs with one-kidney, one clip left ventricular hypertrophy while a similar reduction in arterial pressure with enalapril (20-40 mg/day) would not. Dogs with left ventricular hypertrophy were given metoprolol or enalapril for 5-7 days before a 3-hour coronary occlusion. Infarct size and risk area were measured with triphenyltetrazolium chloride stain and barium angiography, respectively. For control (n = 15), left ventricular hypertrophy (n =17), left ventricular hypertrophy plus metoprolol (n = 12), and left ventricular hypertrophy plus enalapril (n = 15) groups, mean arterial pressure, ratio of infarct size to risk area, and dogs experiencing sudden death were 110 ± 4, 142 ± 4, 121 ± 7, and 120 ± 3 mm Hg; 44 ± 5{\%}, 65 ± 5{\%}, 44{\%} ± 7{\%}, and 30 ± 4{\%}; and 27{\%}, 65{\%}, 17{\%}, and 53{\%}, respectively. Thus, the excessive increase in early mortality occurring when dogs with hypertension and left ventricular hypertrophy undergo coronary occlusion is interrupted with β-blockade, possibly via electrophysiological effects rather than by changes in arterial pressure or infarct size.",
keywords = "Enalapril, Hypertension, Left ventricular hypertrophy, Metroprolol, Occlusions, β-adrenergic blockers",
author = "Dellsperger, {Kevin C} and Martins, {J. B.} and Clothier, {J. L.} and Marcus, {M. L.}",
year = "1990",
month = "1",
day = "1",
doi = "10.1161/01.CIR.82.3.941",
language = "English (US)",
volume = "82",
pages = "941--950",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Incidence of sudden cardiac death associated with hypertension and left ventricular hypertrophy is reduced by chronic β-adrenergic blockade

AU - Dellsperger, Kevin C

AU - Martins, J. B.

AU - Clothier, J. L.

AU - Marcus, M. L.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Because β-adrenergic blockade has as one of its many effects altered electrophysiological abnormalities after dogs with left ventricular hypertrophy have been subjected to coronary occlusion, we tested the hypothesis that metoprolol (200-400 mg/day) would reduce mortality rates in dogs with one-kidney, one clip left ventricular hypertrophy while a similar reduction in arterial pressure with enalapril (20-40 mg/day) would not. Dogs with left ventricular hypertrophy were given metoprolol or enalapril for 5-7 days before a 3-hour coronary occlusion. Infarct size and risk area were measured with triphenyltetrazolium chloride stain and barium angiography, respectively. For control (n = 15), left ventricular hypertrophy (n =17), left ventricular hypertrophy plus metoprolol (n = 12), and left ventricular hypertrophy plus enalapril (n = 15) groups, mean arterial pressure, ratio of infarct size to risk area, and dogs experiencing sudden death were 110 ± 4, 142 ± 4, 121 ± 7, and 120 ± 3 mm Hg; 44 ± 5%, 65 ± 5%, 44% ± 7%, and 30 ± 4%; and 27%, 65%, 17%, and 53%, respectively. Thus, the excessive increase in early mortality occurring when dogs with hypertension and left ventricular hypertrophy undergo coronary occlusion is interrupted with β-blockade, possibly via electrophysiological effects rather than by changes in arterial pressure or infarct size.

AB - Because β-adrenergic blockade has as one of its many effects altered electrophysiological abnormalities after dogs with left ventricular hypertrophy have been subjected to coronary occlusion, we tested the hypothesis that metoprolol (200-400 mg/day) would reduce mortality rates in dogs with one-kidney, one clip left ventricular hypertrophy while a similar reduction in arterial pressure with enalapril (20-40 mg/day) would not. Dogs with left ventricular hypertrophy were given metoprolol or enalapril for 5-7 days before a 3-hour coronary occlusion. Infarct size and risk area were measured with triphenyltetrazolium chloride stain and barium angiography, respectively. For control (n = 15), left ventricular hypertrophy (n =17), left ventricular hypertrophy plus metoprolol (n = 12), and left ventricular hypertrophy plus enalapril (n = 15) groups, mean arterial pressure, ratio of infarct size to risk area, and dogs experiencing sudden death were 110 ± 4, 142 ± 4, 121 ± 7, and 120 ± 3 mm Hg; 44 ± 5%, 65 ± 5%, 44% ± 7%, and 30 ± 4%; and 27%, 65%, 17%, and 53%, respectively. Thus, the excessive increase in early mortality occurring when dogs with hypertension and left ventricular hypertrophy undergo coronary occlusion is interrupted with β-blockade, possibly via electrophysiological effects rather than by changes in arterial pressure or infarct size.

KW - Enalapril

KW - Hypertension

KW - Left ventricular hypertrophy

KW - Metroprolol

KW - Occlusions

KW - β-adrenergic blockers

UR - http://www.scopus.com/inward/record.url?scp=0025111363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025111363&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.82.3.941

DO - 10.1161/01.CIR.82.3.941

M3 - Article

VL - 82

SP - 941

EP - 950

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 3

ER -